PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer

MT Newswires Live02-04 08:55

PYC Therapeutics (ASX:PYC) has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.

The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.

The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.

The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.

The funds will be used to extend the company's cash runway through 2030, enabling the generation of critical human safety and efficacy data across all four of its drug development programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608738211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 08:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608738211","market":"fut","top_or_hot":-1,"title":"PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.</p><p>The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.</p><p>The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.</p><p>The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.</p><p>The funds will be used to extend the company's cash runway through 2030, enabling the generation of critical human safety and efficacy data across all four of its drug development programs.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Secures AU$537 Million Through Institutional Placement, Entitlement Offer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-04 08:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.</p><p>The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.</p><p>The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.</p><p>The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.</p><p>The funds will be used to extend the company's cash runway through 2030, enabling the generation of critical human safety and efficacy data across all four of its drug development programs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608738211","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608738211","pubTimestamp":1770166525,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics  has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.The funds will be used to extend the company's cash runw","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PYC.AU":"PYC THERAPEUTICS LTD","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","BK7067":"生物科技"},"translate_title":"PYC Therapeutics通过机构配售、配股发行获得5.37亿澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYC.AU":1,"LENZ":1.5},"content_text":"PYC Therapeutics (ASX:PYC) has successfully closed its institutional placement, and the institutional component of its three-for-five pro-rata accelerated non-renounceable entitlement offer, raising AU$537 million in commitments at AU$1.50 per new share, according to a Wednesday filing with the Australian bourse.The placement issued around 85.5 million shares to raise AU$128 million, and the institutional entitlement offer issued about 273 million shares to raise AU$409 million, per the filing.The company has satisfied the condition of its AU$200 million underwriting agreement, ensuring it will raise at least AU$600 million from the placement and entitlement offer, including the retail entitlement offer, the filing said.The retail entitlement offer will be conducted at the same price and ratio as the institutional entitlement offer, allowing eligible retail shareholders to participate, and is expected to close on Feb. 27, the filing added.The funds will be used to extend the company's cash runway through 2030, enabling the generation of critical human safety and efficacy data across all four of its drug development programs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608738211","isCrawlerRequest":true}